|
US2090430A
(en)
|
|
1937-08-17 |
|
Lysergic acid amides and process for |
|
US2447214A
(en)
|
|
1948-08-17 |
|
Hoocxchoxxchoxxcooh |
|
US1394233A
(en)
|
|
1921-10-18 |
|
Arthur stoll |
|
US3085092A
(en)
|
|
1963-04-09 |
|
Preparation of lysergic acid deriva- |
|
US2774763A
(en)
|
|
1956-12-18 |
|
Preparation of amides of lysergic age |
|
US2265207A
(en)
|
|
1941-12-09 |
|
D-lysergic acid - d - l-bjtdroxybutyl |
|
US2090429A
(en)
|
|
1937-08-17 |
|
Lysergic acid hydkazide and a |
|
US2438259A
(en)
|
|
1948-03-23 |
|
D-lysergic acid diethyl amide |
|
GB579484A
(en)
|
1943-04-30 |
1946-08-06 |
Sandoz Ltd |
Process for the preparation of diethylamide of d-lysergic acid
|
|
US2809920A
(en)
|
1953-04-10 |
1957-10-15 |
Saul & Co |
Process for the preparation of ergotamine, ergotaminine and ergometrine by saprophytic culture of ergot (claviceps purpurea [fr] tul.) in vitro and isolation of the alkaloids thus produced
|
|
US2796419A
(en)
|
1954-09-27 |
1957-06-18 |
Lilly Co Eli |
Lysergic acid, intermediates and preparation
|
|
US2736728A
(en)
|
1954-12-06 |
1956-02-28 |
Lilly Co Eli |
Preparation of lysergic acid amides
|
|
US2997470A
(en)
|
1956-03-05 |
1961-08-22 |
Lilly Co Eli |
Lysergic acid amides
|
|
US3038840A
(en)
|
1959-07-07 |
1962-06-12 |
Farmaceutici Italia |
Process for the production of alkaloid derivatives of lysergic acid
|
|
FR1338023A
(fr)
|
1962-10-15 |
1963-09-20 |
Farmaceutici Italia |
Nouveau procédé de préparation d'amides d'acide lysergique, substituées ou non
|
|
US3239530A
(en)
|
1964-01-13 |
1966-03-08 |
Sandoz Ltd |
Process for lysergic acid hydrazides
|
|
CH535236A
(de)
|
1970-06-19 |
1973-03-31 |
Sandoz Ag |
Verfahren zur Herstellung neuer reaktionsträger Lysergsäurederivate
|
|
GB1548022A
(en)
|
1976-10-06 |
1979-07-04 |
Wyeth John & Brother Ltd |
Pharmaceutial dosage forms
|
|
US4475196A
(en)
|
1981-03-06 |
1984-10-02 |
Zor Clair G |
Instrument for locating faults in aircraft passenger reading light and attendant call control system
|
|
US4447233A
(en)
|
1981-04-10 |
1984-05-08 |
Parker-Hannifin Corporation |
Medication infusion pump
|
|
US4439196A
(en)
|
1982-03-18 |
1984-03-27 |
Merck & Co., Inc. |
Osmotic drug delivery system
|
|
US4447224A
(en)
|
1982-09-20 |
1984-05-08 |
Infusaid Corporation |
Variable flow implantable infusion apparatus
|
|
US4487603A
(en)
|
1982-11-26 |
1984-12-11 |
Cordis Corporation |
Implantable microinfusion pump system
|
|
US4486194A
(en)
|
1983-06-08 |
1984-12-04 |
James Ferrara |
Therapeutic device for administering medicaments through the skin
|
|
US4959217A
(en)
|
1986-05-22 |
1990-09-25 |
Syntex (U.S.A.) Inc. |
Delayed/sustained release of macromolecules
|
|
US4925678A
(en)
|
1987-04-01 |
1990-05-15 |
Ranney David F |
Endothelial envelopment drug carriers
|
|
US5080646A
(en)
|
1988-10-03 |
1992-01-14 |
Alza Corporation |
Membrane for electrotransport transdermal drug delivery
|
|
US5167616A
(en)
|
1989-12-14 |
1992-12-01 |
Alza Corporation |
Iontophoretic delivery method
|
|
US5225182A
(en)
|
1991-10-31 |
1993-07-06 |
Sharma Yash P |
Vectored drug delivery system using a cephaloplastin linking agent and a methed of using the system
|
|
CA2134611C
(en)
|
1994-10-28 |
2002-12-24 |
Richard John Yarwood |
Process for preparing solid pharmaceutical dosage forms
|
|
US6063908A
(en)
|
1996-07-02 |
2000-05-16 |
Roche Diagnostics Corporation |
Reagents for lysergic acid diethylamide immunoassay
|
|
US20020028942A1
(en)
*
|
1997-01-15 |
2002-03-07 |
Jacewicz Victor Witold |
Novel process and compound
|
|
CA2347469C
(en)
|
1998-10-14 |
2006-02-28 |
Aventis Pharmaceuticals Inc. |
Esters of (+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and their use as prodrugs of the 5ht2a receptor antagonist mdl 100,907
|
|
GB9908014D0
(en)
|
1999-04-08 |
1999-06-02 |
Scherer Corp R P |
Pharmaceutical compositions
|
|
EP1248832A4
(en)
|
2000-01-21 |
2004-07-07 |
Variagenics Inc |
IDENTIFICATION OF THE GENETIC COMPONENTS OF A MEDICINE REACTION
|
|
US6794496B2
(en)
|
2000-04-07 |
2004-09-21 |
Roche Diagnostics Corporation |
Immunoassay for LSD and 2-oxo-3-hydroxy-LSD
|
|
AU2002237548B2
(en)
*
|
2001-03-06 |
2007-04-05 |
Kyowa Hakko Kogyo Co., Ltd. |
Intraorally rapidly disintegrable tablet
|
|
ATE496917T1
(de)
|
2001-12-20 |
2011-02-15 |
Randox Lab Ltd |
Haptene, immunogene, antikörper und konjugate für 2-oxo-3-hydroxy lsd
|
|
GB0210397D0
(en)
|
2002-05-07 |
2002-06-12 |
Ferring Bv |
Pharmaceutical formulations
|
|
JP5348840B2
(ja)
|
2003-02-20 |
2013-11-20 |
メイヨ・ファウンデーション・フォー・メディカル・エデュケーション・アンド・リサーチ |
薬物を選択する方法
|
|
US8012505B2
(en)
|
2003-02-28 |
2011-09-06 |
Alk-Abello A/S |
Dosage form having a saccharide matrix
|
|
WO2005115473A2
(en)
*
|
2004-05-24 |
2005-12-08 |
Nutrinia Ltd. |
Nutritional food and feed, composition, processing and method of use
|
|
ES2651021T3
(es)
|
2004-07-24 |
2018-01-23 |
Laboratorios Del Dr. Esteve, S.A. |
Uso de compuestos activos sobre el receptor sigma para el tratamiento de alodinia mecánica
|
|
US20060039890A1
(en)
|
2004-08-20 |
2006-02-23 |
Renshaw Perry F |
Treatment of psychological and cognitive disorders using a cholesterol -lowering agent in combination with an antidepressant
|
|
JP2006124282A
(ja)
|
2004-10-26 |
2006-05-18 |
Central Glass Co Ltd |
３，３，３−トリフルオロプロピオン酸の製造方法
|
|
US20060167481A1
(en)
|
2005-01-25 |
2006-07-27 |
Esophyx, Inc. |
Slitted tissue fixation devices and assemblies for deploying the same
|
|
US20060223998A1
(en)
|
2005-03-30 |
2006-10-05 |
Fang-Jie Zhang |
Synthetic LSD metabolite for preparing haptens used in an LSD metabolite immunoassay
|
|
GB0511060D0
(en)
|
2005-05-31 |
2005-07-06 |
Novartis Ag |
Organic compounds
|
|
CN101460150B
(zh)
*
|
2006-03-31 |
2014-02-12 |
鲁比康研究私人有限公司 |
用于口腔崩解片剂的可直接压片复合物
|
|
HRP20130713T1
(en)
|
2007-03-19 |
2013-09-30 |
Acadia Pharmaceuticals Inc. |
Combinations of 5-ht2a inverse agonists and antagonists with antipsychotics
|
|
EP2170282A4
(en)
|
2007-06-27 |
2014-11-05 |
Hanmi Pharm Ind Co Ltd |
METHOD FOR PRODUCING A QUICKLY CRUSHING FORMULATION FOR ORAL ADMINISTRATION AND DEVICE FOR PREPARING AND PACKAGING THE FORMULATION
|
|
CN101932577B
(zh)
|
2007-11-30 |
2013-07-17 |
拜耳知识产权有限责任公司 |
杂芳基取代的哌啶
|
|
US9642819B2
(en)
|
2008-07-10 |
2017-05-09 |
Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical |
Low dosage serotonin 5-HT2A receptor agonist to suppress inflammation
|
|
UA103198C2
(en)
|
2008-08-04 |
2013-09-25 |
Новартис Аг |
Squaramide derivatives as cxcr2 antagonists
|
|
JP5690732B2
(ja)
*
|
2008-09-17 |
2015-03-25 |
ザ マクリーン ホスピタル コーポレーション |
群発頭痛障害を治療するための方法及びキット
|
|
WO2010088911A1
(en)
|
2009-02-06 |
2010-08-12 |
Egalet A/S |
Pharmaceutical compositions resistant to abuse
|
|
US10548839B2
(en)
*
|
2010-03-16 |
2020-02-04 |
Wei Tian |
Process of manufacturing a lyophilized fast dissolving, multi-phasic dosage form
|
|
US20120108510A1
(en)
|
2010-05-20 |
2012-05-03 |
Emory University |
Methods of improving behavioral therapies
|
|
CA2816551A1
(en)
|
2010-11-03 |
2012-05-10 |
Mcmaster University |
Method of treating mucosal inflammation
|
|
WO2014059197A1
(en)
|
2012-10-10 |
2014-04-17 |
Henkin Robert I |
Methods and compositions for diagnosing and treating hyposmia
|
|
US9452139B2
(en)
|
2013-03-14 |
2016-09-27 |
Novartis Ag |
Respirable agglomerates of porous carrier particles and micronized drug
|
|
US20140274764A1
(en)
|
2013-03-15 |
2014-09-18 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
|
US20170253928A1
(en)
|
2013-03-15 |
2017-09-07 |
Pathway Genomics Corporation |
Method and system to predict response to treatments for mental disorders
|
|
CN113616883B
(zh)
|
2014-06-30 |
2023-06-06 |
Syqe医药有限公司 |
向受试者肺部递送植物材料中的至少一药理活性剂的系统
|
|
KR20170040800A
(ko)
|
2014-08-13 |
2017-04-13 |
얀센 파마슈티카 엔.브이. |
우울증 치료 방법
|
|
EP2990029A1
(en)
*
|
2014-08-29 |
2016-03-02 |
Sandoz Ag |
Pharmaceutical compositions comprising Canagliflozin
|
|
CN107206093A
(zh)
|
2015-01-28 |
2017-09-26 |
韩国真耐瑞斯有限公司 |
用于治疗神经精神类障碍的组合物及方法
|
|
WO2016145193A1
(en)
*
|
2015-03-10 |
2016-09-15 |
Eleusis Benefit Corporation, Pbc |
Lsd for the treatment of alzheimer's disease
|
|
WO2016168891A1
(en)
|
2015-04-18 |
2016-10-27 |
Baycrest Technology Pty Ltd |
Medication dosing report
|
|
MY189367A
(en)
|
2015-08-12 |
2022-02-08 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
WO2017066488A1
(en)
|
2015-10-13 |
2017-04-20 |
Charleston Laboratories, Inc. |
Treating pain using a composition comprising an opioid and an antiemetic
|
|
US20210069170A1
(en)
|
2016-07-23 |
2021-03-11 |
Paul Edward Stamets |
Tryptamine compositions for enhancing neurite outgrowth
|
|
US20200222656A1
(en)
|
2016-10-18 |
2020-07-16 |
Joseph Rustick |
Method for treatment of depression using synaptic pathway training
|
|
NL2018190B1
(en)
|
2017-01-18 |
2018-07-26 |
Procare Beheer B V |
Psilocybin or psilocin in combination with cannabinoid
|
|
US20190142851A1
(en)
|
2017-11-16 |
2019-05-16 |
CaaMTech, LLC |
Compositions comprising a psilocybin derivative and a cannabinoid
|
|
US11974984B2
(en)
|
2017-02-09 |
2024-05-07 |
Caamtech, Inc. |
Compositions and methods comprising a combination of serotonergic drugs
|
|
NZ757591A
(en)
|
2017-03-30 |
2026-03-27 |
Ojai Energetics Pbc |
Methods and compositions for enhancing health
|
|
US20200147038A1
(en)
|
2017-04-20 |
2020-05-14 |
Eleusis Benefit Corporation, Pbc |
Assessing and treating psychedelic-responsive subjects
|
|
US11471415B2
(en)
|
2017-10-10 |
2022-10-18 |
Douglas Pharmaceuticals, Ltd. |
Extended release pharmaceutical formulation and methods of treatment
|
|
JP2021500948A
(ja)
|
2017-10-19 |
2021-01-14 |
エレウシス ヘルス ソリューションズ ユーエス インコーポレイテッド |
サイケデリック薬剤療法の安全性を向上させる方法およびシステム
|
|
MA50786A
(fr)
|
2017-10-26 |
2022-04-27 |
Blumentech S L |
Produit d'association pour le traitement de troubles neurologiques et/ou psychiatriques
|
|
CA3081626A1
(en)
|
2017-11-07 |
2019-05-16 |
MedReleaf Corp. |
Dosage and varietal recommendations for the treatment of medical conditions using cannabis
|
|
US11367103B2
(en)
|
2020-03-02 |
2022-06-21 |
Yieldmo, Inc. |
Method for modeling digital advertisement consumption
|
|
CA3148256A1
(en)
|
2018-06-21 |
2019-12-26 |
Robert John Petcavich |
Method of inducing dendritic and synaptic genesis in neurodegenerative chronic diseases
|
|
WO2020024977A1
(zh)
|
2018-08-01 |
2020-02-06 |
陕西麦科奥特科技有限公司 |
用于治疗神经系统疾病的化合物及其应用
|
|
MA54877A
(fr)
|
2019-01-30 |
2021-12-08 |
Diamond Therapeutics Inc |
Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
|
|
FI4349407T3
(fi)
|
2019-02-22 |
2025-06-02 |
Gh Res Ireland Limited |
5-metoksi-n,n-dimetyylitryptamiini (5-meo-dmt) vaikean masennuksen hoitoon
|
|
CA3132731A1
(en)
|
2019-03-07 |
2020-09-10 |
University Of Padova |
Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
|
|
US12377112B2
(en)
|
2019-04-17 |
2025-08-05 |
Compass Pathfinder Limited |
Methods of treating neurocognitive disorders, chronic pain and reducing inflammation
|
|
JP2022530390A
(ja)
|
2019-04-24 |
2022-06-29 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
抗精神病剤の応答を予測するための方法
|
|
AU2020274186A1
(en)
|
2019-05-14 |
2021-12-09 |
The Scripps Research Institute |
Compounds for the treatment of neurodegenerative and metabolic disorders
|
|
US20220304980A1
(en)
|
2019-07-04 |
2022-09-29 |
SW Holdings, Inc |
Metered dosing compositions and methods of use of psychedelic compounds
|
|
US20210015738A1
(en)
*
|
2019-07-17 |
2021-01-21 |
Concept Matrix Solutions |
Oral dissolvable film containing psychedelic compound
|
|
GB201911024D0
(en)
|
2019-08-01 |
2019-09-18 |
Beckley Found |
Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
|
|
BR112022002723A2
(pt)
|
2019-08-13 |
2022-07-19 |
Univ Maryland |
Métodos de tratamento de transtornos psicológicos e do cérebro
|
|
US11246860B2
(en)
|
2019-11-07 |
2022-02-15 |
Lophora ApS |
5-HT2A agonists for use in treatment of depression
|
|
JP2023515616A
(ja)
|
2020-02-28 |
2023-04-13 |
ユニヴェルシテートスピタル バーゼル |
５ｈｔ２ａアゴニストの投与後の抑制効果
|
|
GB202003059D0
(en)
|
2020-03-03 |
2020-04-15 |
Beckley Found |
Compounds for use in a method of treating, preventing and/or reducing the symptoms of pain
|
|
CA3175211A1
(en)
|
2020-04-13 |
2021-10-21 |
Matthias Emanuel LIECHTI |
Lsd dose identification
|
|
MX2022012537A
(es)
|
2020-04-16 |
2022-11-07 |
Pike Therapeutics Inc |
Entrega transdermica de microdosis de derivados psicodelicos.
|
|
US20230210762A1
(en)
|
2020-05-01 |
2023-07-06 |
Emergex USA Corporation |
Transdermal drug delivery devices having psilocybin, lysergic acid diethylamide or 3,4-methylenedioxymethamphetamine coated microprotrusions
|
|
WO2021225796A1
(en)
|
2020-05-05 |
2021-11-11 |
Universitätsspital Basel |
Mdma treatment to enhance acute emotional effects profile of lsd, psilocybin or other psychedelics
|
|
WO2021243461A1
(en)
|
2020-06-04 |
2021-12-09 |
Neonmind Biosciences Inc. |
Use of lsd, esa, or dmt for weight loss.
|
|
BR112022025317A2
(pt)
|
2020-06-15 |
2023-01-03 |
Univ Basel |
Método de dosagem de um empatógeno/entactógeno no tratamento de pacientes; método para determinar uma dose de um empatógeno/entactógeno com base no peso corporal, sexo e atividade de cyp2d6; método para refinar a dosagem de um empatógeno/entactógeno; método para predizer a dosagem futura com um empatógeno/entactógeno; método para avaliar a viabilidade de pacientes para receber um empatógeno/entactógeno como tratamento; e método para otimizar o tratamento com empatógeno/entactógeno em um paciente
|
|
EP4167992A1
(en)
|
2020-06-22 |
2023-04-26 |
University of Zürich |
Compositions and kits of parts comprising n,n-dimethyltryptamine and harmine and their use in therapy
|
|
US20210407643A1
(en)
|
2020-06-25 |
2021-12-30 |
Greenway Dna Inc. |
Methods and systems for providing a personalized treatment regimen using cannabinoid or psychedelic compounds
|
|
US20230286975A1
(en)
|
2020-07-07 |
2023-09-14 |
Compass Pathfinder Limited |
Improved method for the production of lysergic acid diethylamide (lsd) and novel derivatives thereof
|
|
EP4188382A4
(en)
|
2020-07-29 |
2024-08-14 |
The Royal Institution for the Advancement of Learning / McGill University |
Administration of modulators of 5-ht and/or ampa receptors for treating neurological conditions
|
|
WO2022023812A1
(en)
|
2020-07-29 |
2022-02-03 |
Diamond Therapeutics Inc. |
Extended release 5-ht receptor agonists for neurological conditions
|
|
JP7584066B2
(ja)
|
2020-08-06 |
2024-11-15 |
株式会社一志精工電機 |
金型構造、プレス加工装置、およびプレス加工方法
|
|
DE202020105085U1
(de)
|
2020-09-03 |
2020-11-30 |
Sophie-Charlotte Adler |
Therapiemethode in Kombination mit psychoaktiver Zusammensetzung
|
|
CN116391128B
(zh)
|
2020-10-24 |
2025-11-21 |
巴塞尔大学医院 |
人血浆中麦角酸二乙基酰胺（lsd）和2,3-二氢-3-羟基-2-氧代麦角二乙胺（o-h-lsd）的定量方法
|
|
WO2022107095A1
(en)
|
2020-11-22 |
2022-05-27 |
Havn Life Sciences Inc. |
Methods and compositions for treating pain with 2-bromo-lysergic acid diethylamide and thymoquinone
|
|
WO2022115796A1
(en)
|
2020-11-30 |
2022-06-02 |
Wesana Health Inc. |
Compositions and methods for treating neurological conditions
|
|
CA3203642A1
(en)
|
2020-12-02 |
2022-06-09 |
The Johns Hopkins University |
Restoration of motor function post-neurological injury using psychedelics
|
|
EP4155306A1
(en)
|
2021-01-15 |
2023-03-29 |
Beckley Psytech Limited |
Neuroactive ergoline analogue
|
|
US20220273628A1
(en)
|
2021-02-19 |
2022-09-01 |
Universitätsspital Basel |
Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
|
|
EP4301464A1
(en)
|
2021-03-06 |
2024-01-10 |
Universitätsspital Basel |
Using geno- or phenotyping to adjust lsd dosing
|
|
CA3215871A1
(en)
|
2021-03-31 |
2022-10-06 |
Lyfe Chng, Llc |
Transdermal system, formulation, and method for the therapeutic administration of a psychedelic agent
|
|
WO2022221942A1
(en)
|
2021-04-19 |
2022-10-27 |
Betterlife Pharma Inc. |
Prevention of drug diversion
|
|
US20230116703A1
(en)
|
2021-04-23 |
2023-04-13 |
Gilgamesh Pharmaceuticals, Inc. |
Novel ergolines and methods of treating mood disorders
|
|
US20240368151A1
(en)
|
2021-04-23 |
2024-11-07 |
Gilgamesh Pharmaceuticals, Inc. |
Novel ergolines and methods of treating mood disorders
|
|
EP4329759A4
(en)
|
2021-04-30 |
2025-07-16 |
Mind Medicine Inc |
CRYSTALLINE FORMS OF LSD SALTS
|
|
JP2024517194A
(ja)
|
2021-05-03 |
2024-04-19 |
マインド メディシン， インコーポレイテッド |
サイケデリック薬の用量を漸増する方法
|
|
US20220362237A1
(en)
|
2021-05-03 |
2022-11-17 |
Mind Medicine, Inc. |
Psychedelics for treatment of pain
|
|
WO2022235500A1
(en)
|
2021-05-03 |
2022-11-10 |
Mind Medicine, Inc. |
Psychedelics for treatment of pain
|
|
US20230301985A1
(en)
|
2021-05-04 |
2023-09-28 |
Mind Medicine, Inc. |
Movement disorders
|
|
US12611399B2
(en)
|
2021-05-04 |
2026-04-28 |
Definium Therapeutics US, Inc. |
Movement disorders
|
|
BR112023024688A2
(pt)
*
|
2021-05-26 |
2024-02-15 |
Mindset Pharma Inc |
Combinação de halucinógeno-ácido graxo
|
|
WO2022261058A1
(en)
|
2021-06-07 |
2022-12-15 |
University Of Mississippi |
Methods for the pulsed delivery of bioactive agents
|
|
WO2022265878A1
(en)
|
2021-06-14 |
2022-12-22 |
Mind Medicine, Inc. |
Controlling effects after 5ht2a agonists administration
|
|
EP4366729A4
(en)
|
2021-07-07 |
2025-06-11 |
Arcadia Medicine, Inc. |
SAFER PSYCHOACTIVE COMPOSITIONS
|
|
WO2023012691A1
(en)
|
2021-08-03 |
2023-02-09 |
Pike Therapeutics, Inc. |
Transdermal micro-dosing delivery of pharmaceutical agents
|
|
WO2023012524A2
(en)
|
2021-08-03 |
2023-02-09 |
Universitatsspital Basel |
Lsd and psilocybin dose equivalence determination
|
|
JP7846211B2
(ja)
|
2021-08-19 |
2026-04-14 |
デフィニウム セラピューティクス ユーエス， インコーポレイテッド |
治療適用のためのｄ－リゼルグ酸ジエチルアミドの即時放出製剤
|
|
WO2023043870A1
(en)
|
2021-09-15 |
2023-03-23 |
Eleusis Therapeutics Us, Inc. |
Chewing gum formulation of lsd and methods of use thereof
|
|
KR20240088949A
(ko)
|
2021-09-20 |
2024-06-20 |
비라이프 테라퓨틱스 인크. |
질병 및 질환의 치료를 위한 lsd 유도체, 합성 및 방법
|
|
WO2023107966A1
(en)
|
2021-12-06 |
2023-06-15 |
Terran Biosciences, Inc. |
Salt and solid forms of lysergic acid diethylamide (lsd) and analogs
|
|
WO2023108277A1
(en)
|
2021-12-14 |
2023-06-22 |
Agile Pharmaceuticals Solutions Inc. |
Cannabinoid and psychedelic formulations comprising hydrotropic agents
|
|
US20250109130A1
(en)
|
2021-12-16 |
2025-04-03 |
Terran Biosciences Inc. |
Isotopically enriched analogs of 2-bromo-lsd, lsd, ald-52, and 1p-lsd
|
|
WO2023114529A2
(en)
|
2021-12-17 |
2023-06-22 |
Bennes, Inc. |
Pharmacoactive formulations for delivery of psychedelic compounds
|
|
WO2023183618A1
(en)
|
2022-03-25 |
2023-09-28 |
Ojai Energetics Pbc |
Psychedelic compositions and methods for forming the same
|
|
US20250295611A1
(en)
|
2022-04-27 |
2025-09-25 |
Tessellate Therapeutics Inc. |
Methods of treating 5ht2a receptor-mediated conditions
|
|
US20230346645A1
(en)
|
2022-05-01 |
2023-11-02 |
Mind Medicine, Inc. |
Method of titrating dose of psychedelics
|
|
JP2025525375A
(ja)
|
2022-06-20 |
2025-08-05 |
マインド メディシン， インコーポレイテッド |
修飾ｌｓｄ様作用を有するリゼルグ酸誘導体
|
|
US20260034058A1
(en)
|
2022-08-09 |
2026-02-05 |
Vitalmelt Ltd. |
Freeze-dried bite with single dose psychedelic
|
|
WO2024229454A2
(en)
|
2023-05-04 |
2024-11-07 |
Gilgamesh Pharmaceuticals, Inc. |
Novel ergolines and methods of treating mood disorders
|
|
WO2024238035A1
(en)
|
2023-05-16 |
2024-11-21 |
Mind Medicine, Inc. |
Movement disorders
|
|
US20250312309A1
(en)
|
2023-06-22 |
2025-10-09 |
Mind Medicine, Inc. |
Allyl-and propargylamine-type phenethylamines and tryptamines for treating medical disorders
|
|
WO2025128594A1
(en)
|
2023-12-11 |
2025-06-19 |
Mind Medicine, Inc. |
Methods of treating generalized anxiety disorder
|